Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the Nucleophilic Defense Against PM Toxicity (NEAT) clinical trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- not stated in abstract (initial analysis of NEAT trial participants)
- Dose used in the study
- 2 g carnosine per day
- Duration
- 12 weeks (samples at 6 and 12 weeks)
- What was measured
- Red blood cell carnosine, urinary carnosine, urinary carnosine-propanol and carnosine-propanal conjugates by LC/MS-MS. Kidney, liver and cardiac function and electrolytes.
What the authors reported
Carnosine roughly doubled red blood cell carnosine and raised urinary carnosine almost sevenfold compared with placebo. Urinary carnosine-propanal nearly doubled; carnosine-propanol did not change. The abstract states no adverse reactions were reported and no effect on kidney, liver or cardiac function or electrolytes. The journal page's full text reports small blood pressure increases (about 4.4 and 2.6 mmHg at one visit) and self-reported tingling and nausea in some participants.
Limits of this study
Interim analysis. Sample size not in abstract. Funded as part of the NEAT trial (NCT03314987). Abstract and full text differ on adverse events.
Source
PubMed 39215872 · doi:10.1007/s00726-024-03414-5
Entry checked against full text (journal site) on 2026-10-11. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.